Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Scott Mcham (NPI 1235170473)

Field	Value
Entity Type	Individual
Organization	Scott Mcham
Address	4101 Tiger Lily Rd Ste 100
City	Lincoln
State	NE
ZIP	68516
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 9, 2006

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

SCOTT MCHAM is enumerated as a Hematology & Oncology Physician (NPI registered 2006-06-09, ~20 years ago) and reports $1.9M in lifetime Medicare revenue with no Medicaid billing on file, making the practice effectively single-payer (Medicare) in the available data. This payer concentration implies operational and revenue exposure primarily to Medicare reimbursement policies and oncology benefit design.

Revenue is highly concentrated in a small set of injectable oncology products: the top three Medicare codes (J9271, J9299, J0897) account for 67.5% of the provider's total Medicare revenue, with J9271 at $602K (33.3%), J9299 at $443.9K (24.6%), and J0897 at $173.9K (9.6%). This concentration indicates the practice's financial performance is driven largely by high-cost oncology biologics and immunotherapies.

The code mix is consistent with an infusion-centered oncology practice: high-revenue monoclonal antibody/immunotherapy codes J9271 (pembrolizumab) and J9299 (nivolumab) dominate, supported by chemotherapy administration codes such as 96413 ($61.9K) and 96365 ($9.6K), and infusion-related services like G0498 ($11.6K). Supportive-care agents and growth factors (J2506 pegfilgrastim $54.3K, J1449 eflapegrastim-xnst $108.9K, J0885 epoetin alfa $16.4K) and biosimilar use (Q5116 trastuzumab-qyyp $46.4K) further indicate routine management of treatment-related neutropenia and targeted/antibody-based regimens.

Competitive standing for the top biologic agents is mixed: J9271 ranks #758 of 1841 providers nationally (58th percentile; typical, unremarkable volume), J9299 ranks #177 of 505 (65th percentile; typical, unremarkable volume), while J0897 ranks #1213 of 10057 (88th percentile; typical, unremarkable volume). These rankings suggest the provider is a modest-to-above-average participant for these agents nationally but not an outlier or dominant national center for pembrolizumab or nivolumab.

The practice shows notably high relative activity for office-based evaluation and chemotherapy throughput: 99214 generates $84.3K and ranks #14238 of 479517 providers (97th percentile; notably above typical national volume) and 96413 generates $61.9K and ranks #313 of 7514 providers (96th percentile; notably above typical national volume). Together these observations point to above-typical outpatient visit intensity and chemotherapy administration volume compared with national peers.

Several ancillary and lab services are reported at high national percentiles, indicating on-site procedural support: venipuncture 36415 (1.6K claims, $12.4K) ranks in the 98th percentile, CBC 85025 ($18.4K) and CMP 80053 ($17.9K) each rank in the 97th percentile, and LDH 83615 ($5.9K) ranks in the 92nd percentile. This constellation supports an operational model that performs in-office blood draws and testing to manage oncology patients during treatment cycles.

The provider reports meaningful use of biosimilars and newer agents: Q5116 (trastuzumab-qyyp biosimilar) contributes $46.4K and ranks #5 of 34 providers nationally (88th percentile; typical, unremarkable volume), and J1449 (eflapegrastim-xnst) contributes $108.9K (6.0%). These patterns suggest the practice incorporates biosimilars and newer supportive-care products into therapy protocols, which may affect drug-cost dynamics and contracting considerations.

Absence of any Medicaid billing on file ("none below") combined with $1.9M in Medicare revenue indicates payer mix is heavily skewed to Medicare. For payers and network planners, this profile signals limited visibility into Medicaid patient flow and suggests negotiations or network access strategies should be calibrated to a predominantly Medicare-driven oncology practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

72 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	14,000	$40	$602K
J9299	Injection, nivolumab, 1 mg	19,300	$20	$443.9K
J0897	Injection, denosumab, 1 mg	9,660	$20	$173.9K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	4,360	$30	$108.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	920	$90	$84.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	660	$90	$61.9K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	620	$90	$54.3K
Q5116	Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg	2,110	$20	$46.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	480	$60	$27.1K
J1439	Injection, ferric carboxymaltose, 1 mg	20,250	$1	$20.3K

Showing 1–10 of 72

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 72 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Scott Mcham — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

72 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	15	30	14,400	$40	$671.6K
J9299	7	10	19,300	$20	$444.5K
G6015	8	10	840	$270	$206.2K
J1449	1	10	3,700	$30	$92.4K
J0897	16	200	2,040	$20	$62.7K
J2506	2	20	460	$90	$40.5K
Q5116	1	10	1,400	$20	$30.7K
J1439	21	30	25,880	$1	$26.4K
J0885	8	10	3,180	$10	$19.2K
96413	4	80	60	$90	$18.2K

Showing 1–10 of 72

Related Providers

Other providers that share a Tax Identification Number (TIN) with Scott Mcham, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bryan Medical Center	NE	General Acute Care Hospital	$0	$56.9M
Phelps Memorial Health Center	NE	Critical Access Hospital	$0	$1.8M
Steven Dunder	NE	Hematology & Oncology Physician	$1.7M	$0
Haris Zahoor	TX	Medical Oncology Physician	$1.6M	$0
Wallace Peterson	NE	Hematology & Oncology Physician	$1.5M	$0
Irfan Vaziri	NE	Medical Oncology Physician	$1.4M	$0
Stacey Knox	NE	Hematology & Oncology Physician	$1.4M	$0
Nathan Green	NE	Hematology & Oncology Physician	$1.1M	$0
Joni Tilford	NE	Hematology & Oncology Physician	$1M	$0
Phelps Memorial Health Center	NE	Rural Health Clinic/Center	$0	$990.6K

Nearby Providers

Other providers in the same ZIP code as Scott Mcham, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Melvin Churchill	NE	Rheumatology Physician	$4.8M	$0
Lincoln Radiology Group PC	NE	Diagnostic Radiology Physician	$0	$4.5M
Elite Professionals Home Care LLC	NE	Home Health Agency	$0	$4.2M
Rick Chatwell	NE	Rheumatology Physician	$3.5M	$0
Lincoln Pediatric Group LLC	NE	Pediatrics Physician	$0	$2.3M
Nebraska House Call Physicians, P.C.	NE	Internal Medicine Physician	$0	$1.7M
Urology Surgical Center LLC	NE	Ambulatory Surgical Clinic/Center	$1.4M	$190.5K
David Brockman	NE	Orthodontics and Dentofacial Orthopedics Dentistry	$0	$1.2M
Phillip Hynes	NE	Radiation Oncology Physician	$1.1M	$0
Milkworks A Nebraska Nonprofit Corporation	NE	Lactation Consultant (Registered Nurse)	$0	$1M

Scott Mcham — Billing Profile & Reimbursement Data

Sign up for Scott Mcham — Billing Profile & Reimbursement Data policy alerts

Scott Mcham — Billing Profile & Reimbursement Data

Sign up for Scott Mcham — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References